The contribution of vascular endothelial growth factor to the induction of regulatory T- cells in malignant effusions

Anticancer Research

Volumn 29, Issue 3, 2009, Pages 881-888

  Wada, Junji ^a   Suzuki, Hiroyuki ^a   Fuchino, Ryouta ^b   Yamasaki, Akio ^a   Nagai, Shuntaro ^a   Yanai, Kousuke ^a   Koga, Kenichiro ^a   Nakamura, Masafumi ^a   Tanaka, Masao ^a   Morisaki, Takashi ^b   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Yakuin CA Clinic   (Japan)

Author keywords

Human FOXP3; IL 10; Immunotherapy; Regulatory T cells; Survival; TGF J5; Tumor immunity; VEGF

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CULTURE; CLINICAL ARTICLE; COLON CANCER; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; EFFUSION; EXPERIMENTAL STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO SELECTION; LIVER CARCINOMA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEURA EFFUSION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; T-LYMPHOCYTES, REGULATORY; VACCINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 64949148656     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Stearns ME, Garcia FU, Fudge K, Rhim J and Wang M: Role of interleukin 10 and transforming growth factor beta 1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice. Clin Cancer Res 5: 711-720, 1999.
2. Morisaki T, Katano M, TJcubo A, Anan K, Nakamura M, Nakamura K, Sato H, Tanaka M and Torisu M: Immunosuppressive cytokines(IL-10, TGF-beta)genes expression in human gastric carcinoma tissues. J Surg Oncol 63: 234-239, 1996.
3. Mocellin S, Wang E and Marincola FM: Cytokines and immune response in the tumor microenvironment. J Immunother 24: 392- 407,2001.
4. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B and Kalthoff H: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7: 925s-932s, 2001.
5. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274, 2005.
6. + regulatory T-cells. J Immunol 177: 896-904, 2006.
7. Bellone G, Smirne C, Mauri F A, Tonel E, Carbone A, Buffolino A, Dughera L, Robecchi A, Pirisi M and Emanuelli G: Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunofher 55: 684-698, 2006.
8. Zitvogel L, Tesniere A and Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727, 2006.
9. Zou W: Regulatory T-cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307,2006.
10. Gajewski TF, Meng Y and Harlin H: Immune suppression in the tumor microenvironment. J Immunother 29: 233-240, 2006.
11. Ohm JE and Carbone DP: VEGF as a mediator of tumor- associated immunodeficiency. Immunol Res 23: 263-272, 2001.
12. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, Ruan ZX, Gao YT and Zheng W: Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 65: 5015- 5019,2005.
13. Kong SY, Park JW, Lee JA, Park JE, Park KW, Hong EK and Kim CM: Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 46: 446-455, 2007.
14. Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, Asomaning K, Lynch TJ, Wain JC and Christiani DC: VEGF polymorphisms and survival in early-stage non- small cell lung cancer. J Clin Oncol 26: 856-862,2008.
15. Ferrara N and Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364,1999.
16. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
17. Saharinen P, Tammela T, Karkkainen MJ and Alitalo K: Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 25: 387-395, 2004.
18. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B and Henriksson R: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 18: 1423-1431, 2000.
19. Goffin JR and Talavera JR: Overstated conclusions of a pooled analysis of bevacizumab in colon cancer. J Clin Oncol 24: 528- 529; author reply 529-530, 2006.
20. + regulatory T-cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 782:18-32,2001.
21. Maloy KJ and Powrie F: Regulatory T-cells in the control of immune pathology. Nat Immunol 2: 816-822, 2001.
22. Coutinho A, Hori S, Carvalho T, Caramalho I and Demengeot J: Regulatory T-cells: the physiology of autoreactivity in dominant tolerance and "quality control" of immune responses. Immunol Rev 182: 89-98,2001.
23. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia J R, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W: Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
24. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T-cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464, 2005.
25. high T-cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 177: 7398-7405, 2006.
26. high regulatory T-cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55: 1064-1071,2006.
27. Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, Warren BF, Piris J, Roncador G, Fox SB, Banham AH and Cerundolo V: Increased frequency of regulatory T-cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 7: 7, 2007.
28. + regulatory T-cells in patients with multiple myeloma. Blood 107: 3940-3949, 2006.
29. + regulatory T-cells in tumor immunity. Curr Top Microbiol Immunol 293: 287-302, 2005.
30. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T and Nakayama E: Tumor rejection by in vivo administration of anti- CD25(interleukin-2 receptor alpha)monoclonal antibody. Cancer Res 59: 3128-3133, 1999.
31. + T-cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218,1999.
32. + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32: 3267-3275,2002.
33. + regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2: 1, 2002.
34. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R and Melief CJ: Synergism of cytotoxic T-lymphocyte-associated antigen 4 blockade and depletion of CD25(+)regulatory T-cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T-lymphocyte responses. J Exp Med 194: 823-832,2001.
35. + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201: 779-791, 2005.
36. + regulatory T-cells. J Exp Med 202: 885-891, 2005.
37. Beyer M and Schultze J L: Regulatory T-cells in cancer. Blood 108: 804-811,2006.